BR112022017678A2 - Expressão sob demanda de fatores exógenos em linfócitos para tratar hiv - Google Patents

Expressão sob demanda de fatores exógenos em linfócitos para tratar hiv

Info

Publication number
BR112022017678A2
BR112022017678A2 BR112022017678A BR112022017678A BR112022017678A2 BR 112022017678 A2 BR112022017678 A2 BR 112022017678A2 BR 112022017678 A BR112022017678 A BR 112022017678A BR 112022017678 A BR112022017678 A BR 112022017678A BR 112022017678 A2 BR112022017678 A2 BR 112022017678A2
Authority
BR
Brazil
Prior art keywords
lymphocytes
hiv
exogenous factors
treat hiv
expression
Prior art date
Application number
BR112022017678A
Other languages
English (en)
Inventor
Li Haishan
Lahusen Tyler
David Pauza Charles
Original Assignee
American Gene Tech Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Gene Tech Int Inc filed Critical American Gene Tech Int Inc
Publication of BR112022017678A2 publication Critical patent/BR112022017678A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

EXPRESSÃO SOB DEMANDA DE FATORES EXÓGENOS EM LINFÓCITOS PARA TRATAR HIV. A presente invenção refere-se, geralmente, à imunização e à imunoterapia para o tratamento ou inibição de HIV. Nas modalidades, vetores virais são revelados, os quais compreendem porções de carga terapêutica compreendendo uma sequência de nucleotídeos que codifica pelo menos um fator exógeno solúvel capaz de inibir a infecção por HIV e um promotor responsivo à célula T, que regula a expressão da sequência de nucleotídeos.
BR112022017678A 2020-03-03 2021-03-03 Expressão sob demanda de fatores exógenos em linfócitos para tratar hiv BR112022017678A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062984716P 2020-03-03 2020-03-03
PCT/US2021/020721 WO2021178571A1 (en) 2020-03-03 2021-03-03 On demand expression of exogenous factors in lymphocytes to treat hiv

Publications (1)

Publication Number Publication Date
BR112022017678A2 true BR112022017678A2 (pt) 2022-11-08

Family

ID=77614437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017678A BR112022017678A2 (pt) 2020-03-03 2021-03-03 Expressão sob demanda de fatores exógenos em linfócitos para tratar hiv

Country Status (10)

Country Link
US (1) US20240141374A1 (pt)
EP (1) EP4114439A4 (pt)
JP (1) JP2023516685A (pt)
KR (1) KR20220150320A (pt)
CN (1) CN115551532A (pt)
AU (1) AU2021232603A1 (pt)
BR (1) BR112022017678A2 (pt)
CA (1) CA3170630A1 (pt)
IL (1) IL296096A (pt)
WO (1) WO2021178571A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965357T3 (es) 2016-01-15 2024-04-15 American Gene Tech Int Inc Métodos y composiciones para la activación de linfocitos T gamma-delta
EP3426777B1 (en) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
BR112022023410A2 (pt) * 2020-05-19 2022-12-20 Ixaka France Sequências de promotores para expressão in vitro e in vivo de produtos de terapia gênica em células cd3+

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2265460A1 (en) * 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Aav4 vector and uses thereof
AU2002363465A1 (en) * 2001-10-25 2003-05-19 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
BR0308896A (pt) * 2002-05-07 2007-01-09 Chiron Corp complexos e hìbridos envelope do hiv-cd4
US9719106B2 (en) * 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
CA2999496A1 (en) * 2015-09-22 2017-03-30 The Trustees Of The University Of Pennsylvania Method of redirecting t cells to treat hiv infection
WO2017213697A1 (en) * 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
WO2018009246A1 (en) * 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
BR112019014082A2 (pt) * 2017-01-09 2020-03-03 American Gene Technologies International Inc. Imunoterapia para hiv sem etapa de pré-imunização
CA3064442A1 (en) * 2017-06-16 2018-12-20 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
WO2019191314A1 (en) * 2018-03-27 2019-10-03 American Gene Technologies International Inc. Methods of manufacturing genetically-modified lymphocytes
KR20210031898A (ko) * 2018-07-13 2021-03-23 난징 레전드 바이오테크 씨오., 엘티디. 전염병을 치료하기 위한 공동수용체 시스템

Also Published As

Publication number Publication date
JP2023516685A (ja) 2023-04-20
US20240141374A1 (en) 2024-05-02
AU2021232603A1 (en) 2022-10-20
WO2021178571A1 (en) 2021-09-10
IL296096A (en) 2022-11-01
EP4114439A4 (en) 2024-04-17
EP4114439A1 (en) 2023-01-11
CN115551532A (zh) 2022-12-30
KR20220150320A (ko) 2022-11-10
CA3170630A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
BR112022017678A2 (pt) Expressão sob demanda de fatores exógenos em linfócitos para tratar hiv
BR112022014884A2 (pt) Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave
BR112022009895A2 (pt) Construtos de terapia de gene de microdistrofina e usos dos mesmos
BR112019001887A2 (pt) composições e métodos para o tratamento de doença associada a cep290
BR112019004770A2 (pt) anticorpos do vírus antidengue, polipeptídeos contendo regiões fc variantes, e métodos de uso
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
BR112016019068A2 (pt) construto, vetor recombinante, composição farmacêutica, método de inibição de replicação viral ou expressão de uma sequência alvo em uma célula infectada com um vírus, polipeptídeo de sau cas9 recombinante, construto de sau cas9 recombinante, construto recombinante para expressão de um rna guia individual e kit
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
BR112017019625A2 (pt) udp-glicosiltransferases
CO2022013121A2 (es) Vacuna 2019-ncov (sars-cov-2)
BR112022026127A2 (pt) Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
BR112022022503A2 (pt) Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2
BR112018075855A2 (pt) sistema de vetor viral adeno-associado com dupla sobreposição para a expressão abc4a
BR112018001121A2 (pt) vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico
BR112018075692A2 (pt) genes cln1 otimizados e cassetes de expressão e seu uso
BR112018074930A2 (pt) ácido nucleico, vetor de ácido nucleico, partícula de entrega, composição farmacêutica, célula hospedeira, método para edição do genoma e método e kit para prevenção e/ou tratamento de uma doença
BR112021020727A2 (pt) Materiais e métodos para produção de proteína
BR112021021720A2 (pt) Composições úteis para tratamento de doença de pompe
BR112023022481A2 (pt) Métodos de tratamento de cânceres com mutação de perda de função bialélica ou de superexpressão gênica
BR112016015678B1 (pt) Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica
BR112022014552A2 (pt) Polipeptídeo recombinante, composição farmacêutica, método de prevenção ou tratamento de uma infecção viral em um indivíduo que necessita do mesmo, molécula de rna, composição terapêutica, sistema de expressão, polipeptídeo recombinante para tratar infecção por sars-cov-2 e polinucleotídeo que codifica o polipeptídeo recombinante
BR112018068890A2 (pt) dna polimerases marinhas
BR112021024285A2 (pt) Vetores aav com promotor da proteína zero da mielina e usos dos mesmos para tratar doenças associadas a células de schwann como doença de charcot marie tooth
BR112021024855A2 (pt) Composições de vírus adenoassociados para transferência de gene arsa e métodos de uso das mesmas